title: Features associated with survival and disease-free survival in early endometrial cancer.
abstract: Age, clinical stage, histologic grade, depth of myometrial penetration, adnexal status, peritoneal cytology, and progesterone and estrogen receptor status were available for 139 patients with clinical stage IA, IB, or II endometrial adenocarcinoma who had therapy at Indiana University Hospital or St. Vincent Hospital in Indianapolis. These features were analyzed for their association with survival and disease-free survival. Patients treated at Indiana University Hospital were similar to those from St. Vincent Hospital when comparisons were made by chi 2 test for age, clinical stage, grade, adnexal metastases, peritoneal cytologic results, progesterone receptor status, or estrogen receptor status. However, patients treated at Indiana University Hospital had lesions that were deeper (p = 0.03) than those treated at St. Vincent Hospital. Survival differences were observed for patients with progesterone receptor-rich versus progesterone receptor-poor tumors (p = 0.004), grades 1 and 2 versus grade 3 lesions (p = 0.013), and malignant versus benign peritoneal cytologic results (p = 0.01). Differences in disease-free survival were observed for those patients with adnexal metastases versus those with no adnexal disease (p = 0.002), those with estrogen receptor-rich versus estrogen receptor-poor tumors, outer third myometrial invasion (p = 0.002), and patients with clinical stage I versus clinical stage II disease (p = 0.03). A stepwise Cox proportional hazards model was constructed to determine correlates of disease-free survival. In the final model, grade (p = 0.0002), peritoneal cytologic results (p = 0.0002), progesterone receptor status (p = 0.004), and age as a continuous variable (p = 0.008) were most closely associated with disease-free survival.
authors.affiliation: Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis.
authors.forename: G P
authors.initials: GP
authors.lastname: Sutton
authors.forename: H E
authors.initials: HE
authors.lastname: Geisler
authors.forename: F B
authors.initials: FB
authors.lastname: Stehman
authors.forename: P C
authors.initials: PC
authors.lastname: Young
authors.forename: T M
authors.initials: TM
authors.lastname: Kimes
authors.forename: C E
authors.initials: CE
authors.lastname: Ehrlich
mesh_terms: D000230:Adenocarcinoma / Q000032:analysis / Q000401:mortality* / Q000473:pathology; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D003581:Cytodiagnosis; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010529:Peritoneal Cavity / Q000166:cytology; D011379:Prognosis; D011980:Receptors, Progesterone / Q000032:analysis; D014594:Uterine Neoplasms / Q000032:analysis / Q000401:mortality* / Q000473:pathology; D014599:Uterus / Q000473:pathology
chemical_list: D011980:Receptors, Progesterone